CLOSING THE GAPS IN TB AND DR-TB TESTING AND TREATMENT

KEY INDICATORS IN 29 COUNTRIES SURVEYED

**MDR-TB TREATMENT COVERAGE**
(percentage of people who started MDR-TB treatment relative to estimated incidence of MDR-TB)

**TB/HIV CO-INFECTION RATE**
(percentage of people with TB who are estimated to be HIV-positive)

**GAP BETWEEN ESTIMATED AND DETECTED CASES**
(percentage of people estimated to have TB that are missing in the country’s case detection rates)

**WHO HIGH TB OR HIGH TB/HIV OR HIGH MDR-TB BURDEN COUNTRIES**

**SOURCES:** All information is from 2015 except where noted. WHO (http://www.who.int/tb/country/data/download/en) (Accessed 2017 May 31)

**DISCLAIMER:** Boundaries used on this map do not imply the expression of any opinion whatsoever on the part of the Stop TB Partnership concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers or boundaries.

**WHO HIGH TB OR HIGH TB/HIV OR HIGH MDR-TB BURDEN COUNTRIES**

- Afghanistan
- Armenia
- Bangladesh
- Belarus
- Brazil
- Cambodia
- Central African Republic
- China
- Democratic Republic of the Congo
- Ethiopia
- Georgia
- India
- Indonesia
- Kazakhstan
- Kenya
- Kyrgyzstan
- Mozambique
- Myanmar
- Nigeria
- Pakistan
- Papua New Guinea
- Philippines
- Russian Federation
- South Africa
- Swaziland
- Tajikistan
- Ukraine
- Vietnam
- Zimbabwe

**Estimated TB incidence rate per 100,000 population**
- 10–19
- 20–49
- 50–124
- 125–299
- 300–499
- ≥500

**Number of GeneXpert MTB/RIF modules for rapid molecular testing procured (2010–2016)**
- 1–16
- 17–100
- 101–500
- >500

**SOURCES:**
Data on procurement of GeneXpert MTB/RIF modules were obtained from its manufacturer Cepheid.